论文部分内容阅读
糖尿病特别是2型糖尿病(T2DM)的患病率在全球不断增加,而近期的流行病学研究发现糖尿病与癌症的发病率相关。由于胰岛素不仅可以调控代谢,还有促有丝分裂作用,并且早期流行病学证据表明一些外源性的胰岛素治疗与癌症的风险增加相关,胰岛素治疗的安全性引起了广泛关注。地特胰岛素作为一种新型的长效基础胰岛素,多个体外细胞学及患者血清学研究证实其促有丝分裂作用弱于人胰岛素,并且临床试验的荟萃研究也支持地特胰岛素使用者的
The prevalence of diabetes, especially type 2 diabetes mellitus (T2DM), is increasing globally, and recent epidemiological studies have found that diabetes is associated with the incidence of cancer. Since insulin not only regulates metabolism but also mitosis, and early epidemiological evidence suggests that some exogenous insulin therapies are associated with an increased risk of cancer, the safety of insulin therapy has drawn much attention. Detemir, a new long-acting basal insulin, has been demonstrated by several in vitro cytology and patient serological studies to demonstrate weaker mitogenic effects than human insulin, and a meta-study of clinical trials also supports the use of detemir users